Latest News

Since its introduction in the early 1980s, intravesical instillation of live bacillus Calmette-Guérin (BCG) remains the gold standard immunotherapeutic approach for eradication of carcinoma-in-situ of the bladder and for prevention of recurrence for patients with papillary high-risk non-muscle invasive bladder cancer (NMIBC). Despite the success of BCG, response is not uniform and limited options exist […]

On 8-12 July, the EAU hosted its 36th Annual EAU Congress, the Virtual EAU21. Over 6000 delegates from all around the world joined the five-day online programme. If you’re interested in our “as it happened” live coverage of the congress, you can find the following reports on the EAU21 Congress site:   Thursday, 8 July EAU21 […]

(UroToday.com) Dr. Laurence Albiges discussed the evolving landscape of first-line systemic treatment in metastatic renal cell carcinoma (mRCC) at the European Association of Urology’s (EAU) 2021 annual meeting’s controversies in onco-urology session. Dr. Albiges started by highlighting the new guidelines adapted from the EAU and ESMO guidelines for RCC, using the IMDC risk classification to select […]

(UroToday.com) In the Prostate Cancer Detection by MR, PET, and Micro-US Imaging session at the 2021 European Association of Urology annual meeting, Dennie Meijer presented a discussion of a study in which the authors aimed to identify predictors of biochemical recurrence (BCR) in patients who opt for robot-assisted laparoscopic radical prostatectomy (RARP) for localized prostate cancer […]

(UroToday.com) While conventional staging studies remain the standard of care, PSMA testing will likely drastically change the landscape of prostate cancer evaluation, as it is clearly more sensitive than conventional imaging. Intraprostatic PSMA intensity, as measured by standardized uptake values (SUV), are potentially associated with clinically relevant oncological outcomes for prostate cancer.

(UroToday.com) In this study, the authors aimed to investigate the accuracy of 18F-DCFPyl-PSMA-PET/CT to detect and localize prostate lesions compared to multiparametric MRI (mpMRI) in men with suspected prostate cancer.

(UroToday.com) Relugolix is a novel oral LHRH agonist, compared to the LHRH agonist degarelix which had to be injected. Degarelix is associated with high rates of injection site-reaction. Recently, the FDA approved relugolix, an oral GnRH antagonist, for the treatment of advanced prostate cancer patients.

Endocorporeal Laser Lithotripsy (ELL) was firstly described in 1992, having the Holmium: Yttrium-Aluminium-Garnet(Ho: YAG) pulsed laser as a pioneer in the field and then, turning into the current gold standard laser for this procedure. Thanks to the technological advances, nowadays we have a new pulsed laser gaining access in ELL, the Thulium Fiber Laser (Tm-Fiber). […]

The Controversies in Onco-Urology session at the European Association of Urology 2021 virtual annual meeting included a presentation by Dr. Cedric Poyet who discussed the optimal timing of perioperative systemic therapy for high-risk upper tract urothelial carcinoma. Dr. Poyet notes that the definition of high-risk upper tract urothelial carcinoma includes cM0, pT2-T4 pN0-N3 or pTanyN1-N3, […]

(UroToday.com) The detection of recurrence and salvage treatment options after primary treatment for prostate cancer session at the European Association of Urology 2021 annual meeting included a presentation by Dr. Maria Ferriero discussing a prospective study assessing post-prostatectomy detection rate of presumed local failure at mpMRI with 18F-choline, 64Cu-Cl2 or 64Cu-PSMA PET/CT. 64Cu-Cl2 or 64Cu-PSMA […]